SCHEMBL20069573

SCHEMBL20069573

Cc1ccnc(C(=O)N2C3CC2CN(C)C3)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.46
RET P07949 1/20 0.42
PDE2A O00408 1/20 0.40
CSF1R P07333 1/20 0.39
GRM5 P41594 1/20 0.36
CCR1 P32246 1/20 0.36
CCR5 P51681 1/20 0.36
CCR8 P51685 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
CTSA P10619 1/20 0.34
HCRTR1 O43613 2/20 0.34
HCRTR2 O43614 2/20 0.34
LRRK2 Q5S007 1/20 0.34
BRD4 O60885 1/20 0.34
SOS1 Q07889 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20153138 0.88 PDE10A (0.45) PDE10ARETPDE2ACSF1RGRM5
SCHEMBL20148714 0.85 PDE10A (0.43) PDE10ARETPDE2ACSF1RGRM5
SCHEMBL20070532 0.83 MGLL (0.46) RETCSF1RGRM5CCR1CCR5
SCHEMBL20069577 0.80 L3MBTL1 (0.51) PDE10ARETGRM5ALDH1A1LMNA
SCHEMBL20069581 0.79 TDP1 (0.44) PDE10ARETCSF1RHCRTR2BRD4
SCHEMBL20069571 0.73 PDE10A (0.44) PDE10ARETPDE2ACSF1RGRM5
SCHEMBL20069584 0.72 P2RX7 (0.43) RETPDE2AALDH1A1HCRTR1HCRTR2
SCHEMBL20069583 0.72 PDE10A (0.46) PDE10ARETPDE2ACSF1RGRM5
SCHEMBL20070448 0.71 HPGD (0.51) RETALDH1A1SMN1; SMN2
SCHEMBL21159149 0.71 RET (0.47) RETCSF1RGRM5CCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3753939-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma Inc. (US) 2020-12-23 EP disclosed
EP-3523301-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-05-27 EP disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
WO-2018071447-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF PDE10A 822/4885RET 1/4885PDE2A 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.